Olanzapine/fluoxetine
Overview
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.[1]
Uses, dosage and effects
Medical uses
Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression.[2]
Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).[5–8] WP
Risks and side effects
Side effects
Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine (side effects) and fluoxetine (side effects). Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision, and difficulty concentrating.[2] WP
Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine.[9] WP
Olanzapine is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring.[9] WP
In rare cases, olanzapine/fluoxetine may cause neuroleptic malignant syndrome.[2] WP
Like other SSRIs, olanzapine/fluoxetine carries a boxed warning stating that it could increase the risk of suicidal thoughts and behaviors in patients aged 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.[2] WP
Chemistry
Harm reduction information
No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
Sources
- Other Tratamento medicamentoso dos transtornos bipolares - Transtornos psiquiátricos
- Journal / agency Symbyax- olanzapine and fluoxetine hydrochloride capsule. 21 April 2020
- Journal / agency Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. The Journal of Clinical Psychiatry. October 2009. doi:10.4088/JCP.08m04772gre · PMID 19906346
- Other Grohol, J. FDA Approves Symbyax for Treatment Resistant Depression
- Journal / agency McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disorders. 2003. doi:10.1111/j.1399-2406.2003.00061.x · PMID 14700010
- Journal / agency Pederson KJ, Roerig JL, Mitchell JE. Towards the pharmacotherapy of eating disorders. Expert Opinion on Pharmacotherapy. October 2003. doi:10.1517/14656566.4.10.1659 · PMID 14521477
- Journal / agency Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. The Journal of Clinical Psychiatry. July 2000. doi:10.4088/JCP.v61n0709 · PMID 10937610
- Journal / agency Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. The American Journal of Psychiatry. October 2002. doi:10.1176/appi.ajp.159.10.1777 · PMID 12359687
- Other Symbyax
Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.